Dr. Griffin’s Lab and Lab work

Robert J. Griffin, Ph.D., is a Professor of radiation and cancer biology in the Department of Radiation Oncology with over 20 years of experience as a radiation biologist.  Much of his work has been studying the interactions of normal and tumor microvasculature with tumor cells, blood flow, hypoxia and the general tumor microenvironment and using various nanomaterials (e.g., nanoliposomes and various nanomedicines) for targeted delivery to the tumor vasculature and improvement of responses to radiation, thermal treatment, or chemotherapy. He has a number of recent publications on a gold-cytokine nanoparticles, which are in stage II clinical trials and was successfully tested as a light-activated (laser-induced PT and nanobubble phenomenon) nanodrug. Dr. Griffin has published numerous peer-reviewed articles on the anti-angiogenic/vascular targeting of myeloma and breast cancer models and the development of labeled compounds for PET imaging of these tumor types or photoacoustic detection of particle-based nanodrugs. He has been on over 10 PhD thesis committees, has been the major advisor for 3 PhD students, and mentored 3 junior faculty in his research group into successful faculty positions and NIH funding, including an R21 related to the nanobiology of cancer and drug delivery as well as the effects of radiation on systemic bone biology and the microbiome influence on cancer development. He has acted as President and program chair for the Society for Thermal Medicine, which has an emphasis on nanotechnology for thermal treatments in a variety of modalities.   He is active on the program committee for the ASTRO refresher course and the Radiation Research society as well as on the annual meeting and scientific council committees for ASTRO.   Currently, he is also an associate senior editor for Technology in Cancer Research and Treatment and for the International Journal of Radiation Oncology, Biology and Physics (Red Journal).